about
Renal outcome in adults with renal insufficiency and irregular asymmetric kidneysDetermination of the production rate and non-renal clearance of cystatin C and estimation of the glomerular filtration rate from the serum concentration of cystatin C in humansEstimation of glomerular filtration rate in cancer patientsPopulation pharmacokinetics and pharmacodynamics of oral etoposideA phase I trial of dose-dense (biweekly) carboplatin combined with paclitaxel and pegfilgrastim: a feasibility study in patients with untreated Stage III and IV ovarian, tubal or primary peritoneal cancer: a Gynecologic Oncology Group study.Digoxin population pharmacokinetics from routine clinical data: role of patient characteristics for estimating dosing regimens.Paclitaxel and carboplatin as first-line chemotherapy combined with gefitinib (IRESSA) in patients with advanced breast cancer: a phase I/II study conducted by the Hellenic Cooperative Oncology Group.Evaluation of the Modified Diet in Renal Disease equation for calculation of carboplatin dose.Weekly paclitaxel plus carboplatin is an effective nonanthracycline-containing regimen as neoadjuvant chemotherapy for breast cancer.A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients with solid tumoursA phase I study with an expanded cohort to assess the feasibility of intraperitoneal carboplatin and intravenous paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: A Gynecologic Oncology Group study.Feasibility study of paclitaxel plus carboplatin in patients with endometrial cancer: a Japan Kanto Tumor Board study (JKTB trial).A phase II study of modified dose-dense paclitaxel and every 4-week carboplatin for the treatment of advanced-stage primary epithelial ovarian, fallopian tube, or peritoneal carcinoma.A phase II trial of dose-dense (biweekly) paclitaxel plus carboplatin as neoadjuvant chemotherapy for operable breast cancer.Myelosuppression by chemotherapy in obese patients with gynecological cancers.Population-based investigations of drug relative clearance using nonlinear mixed-effect modelling from information generated during the routine clinical care of patients.Phase II evaluation of paclitaxel and carboplatin in the treatment of carcinosarcoma of the uterus: a Gynecologic Oncology Group study.Population pharmacokinetics of tenofovir in human immunodeficiency virus-infected patients taking highly active antiretroviral therapy.Population pharmacokinetic analysis of vancomycin in patients with hematological malignanciesPrediction of creatinine clearance from plasma creatinine: comparison of five formulae.Evaluation of a microcomputer program (OPT) for parameter optimisation in clinical pharmacokinetics: gentamicin and tobramycin.Re-examination of digoxin dosage regimen: comparison of the proposed nomograms or formulae in elderly patients.Prospective comparative study of variable dosage and variable frequency regimens for administration of gentamicin.Population pharmacokinetics of tigecycline in patients with complicated intra-abdominal or skin and skin structure infections.Gastrointestinal disease control after histamine2-receptor antagonist dose modification for renal impairment in frail chronically ill elderly patients.Kidney function, endothelial activation and atherosclerosis in black and white Africans with rheumatoid arthritisHigh-dose chemotherapy and stem cell transplantation for advanced testicular cancerImpact of obesity on chemotherapy management and outcomes in women with gynecologic malignanciesQuantitative justification for target concentration intervention--parameter variability and predictive performance using population pharmacokinetic models for aminoglycosides.Exposure-response analyses of tigecycline efficacy in patients with complicated skin and skin-structure infections.Accurate measurement of individual glomerular filtration rate in cancer patients: an ongoing challenge.A multicentre phase II study of carboplatin and prolonged oral etoposide in the treatment of cancer of unknown primary site (CUPS)Variability of glomerular filtration rate estimation equations in elderly Chinese patients with chronic kidney disease.Correlation of aminoglycoside dosages with serum concentrations during therapy of serious gram-negative bacillary diseaseCarboplatin plus paclitaxel in extensive small cell lung cancer: a multicentre phase 2 study.Estimation of glomerular filtration rate in paediatric cancer patients using 51CR-EDTA population pharmacokineticsRounding of low serum creatinine levels and consequent impact on accuracy of bedside estimates of renal function in cancer patients.Tolerance to chemotherapy in elderly patients with cancer.Weekly paclitaxel and carboplatin (PC-W) for patients with primary advanced ovarian cancer: results of a multicenter phase-II study of the NOGGO.OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer.
P2860
Q24791709-BA10F760-CD42-4D98-AF31-6002217139E4Q28262338-60D6CD22-E575-4347-A419-20250544F249Q28350826-621253AB-892A-4B7F-866B-7564BBC9F902Q28365888-5649FECB-EDAC-46AD-95EB-C924CA2568C5Q30430866-D4F002C8-9F0A-4049-B461-4D1B247B9FA6Q30841916-7AA69E99-4647-45E4-9D98-3943149326F7Q33366949-0268198E-9378-44FA-872C-E61AF78F83ABQ33383126-9226C8DC-2993-4C56-943B-0B6FFC8D7B33Q33388534-CBF4807B-EA5C-45D0-8192-B147000486B6Q33390447-812D85E7-6F79-4A25-A060-F1E52C16F465Q33393909-BDEAC000-4CCB-4240-BE9F-F91615B93FB2Q33401454-3035595D-148F-434D-8D2A-3663A1996CBAQ33407574-A3AF0E29-3643-4BE0-8219-63651A915AE0Q33430463-7DB4AB84-333D-4D6C-A130-CD77FED10EDBQ33434316-52DA5098-579C-4B96-98A5-1C7A340D8E54Q33668845-7D74BCD6-E1C9-4F38-81F6-F6D56AFD903EQ33898174-9DE1930C-A853-4BD0-ACC7-57C5A9F010DCQ33938112-94CE9F25-9EEF-41D6-A625-7B028FA06587Q34228227-D6D36551-D3CA-4349-B8AF-B2F3724C62C6Q34397729-5D27CEFB-1A27-4B3F-9578-9FE261E5334AQ34417050-CA28B812-3AE4-45F9-ABED-FDA287E96765Q34449966-72AAB23F-6151-4BD5-880E-309BA73E07B4Q34948994-F0EBA204-EE1F-4C23-A613-DCC686822EC2Q35127941-5AA1F0EA-53C6-490B-B651-8FEA2D51CE08Q35129789-EF99132D-1AC3-487D-B77D-077C1D9FDB89Q35217530-D5F0C21E-7C2F-49FD-BAF4-64F02FD11871Q35660641-3D243F52-D111-4475-8636-52ADC115DA4CQ35748477-BAC63095-1E79-4C78-B8B5-2E17C1B4EAE5Q35826231-4E9ED0FE-80D4-4219-9A0F-DD3A91FA508EQ35840772-ED4723EB-5423-47D2-92D1-EA352C625C5BQ36192043-3C5DC33F-7E16-4B05-BC63-6095C16DFDDAQ36292993-ECC9CA25-967A-49B2-B163-19018BE1A882Q36326390-F8C34736-A728-4EE4-9B4D-D005E3823D0AQ36483889-21121892-1AFF-4659-BE86-A23ECA4F1050Q36622150-BC6CC733-5D05-4DE6-94DB-4625CB700E33Q36673641-989C642D-B8FE-494C-89BA-215064E83BD0Q36694636-48AAD233-9FD3-4743-9F8E-ACE78988CA17Q36715266-A95EC74A-CB86-4131-AE91-DEABD5A45DF0Q36773602-06D8CABF-B3D2-49E5-81B8-AE5BBF0C21B9Q36822179-8CE17FFC-37A5-4174-A1BD-746E7C915381
P2860
description
1973 nî lūn-bûn
@nan
1973年の論文
@ja
1973年学术文章
@wuu
1973年学术文章
@zh
1973年学术文章
@zh-cn
1973年学术文章
@zh-hans
1973年学术文章
@zh-my
1973年学术文章
@zh-sg
1973年學術文章
@yue
1973年學術文章
@zh-hant
name
Letter: Creatinine clearance: bedside estimate.
@en
Letter: Creatinine clearance: bedside estimate.
@nl
type
label
Letter: Creatinine clearance: bedside estimate.
@en
Letter: Creatinine clearance: bedside estimate.
@nl
prefLabel
Letter: Creatinine clearance: bedside estimate.
@en
Letter: Creatinine clearance: bedside estimate.
@nl
P1476
Letter: Creatinine clearance: bedside estimate.
@en
P2093
Jelliffe RW
P304
P356
10.7326/0003-4819-79-4-604
P407
P577
1973-10-01T00:00:00Z